2026-04-11T09:59:22Z https://pub.unibl.org/oai

oai:pub.unibl.org:41414 2024-06-12T14:25:49Z

SAT0152 A Randomised,Doble-Blind ,Phase III Study Comparing SB2,An Infliximab Biosimilar, To the Infliximab Reference Product (Remicade) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy /unibl/author/JY Choe /unibl/author/Nenad Prodanović /unibl/author/j Niebrizidovski /unibl/author/i Staykov /unibl/author/E Dokoupilova /unibl/author/A Baranauskaite /unibl/author/R Yatsyshyn /unibl/author/M Mekić /unibl/author/W Porawska /unibl/author/H Ciferska /unibl/author/K Jedrichovicz-Rosiak /unibl/author/A Zielinska /unibl/author/J Choe /unibl/author/YH Rho /unibl/author/JS Smolen 2015-06 Academic Article text 10 10 /unibl/sci/idNaucniRad:25134 ANNALS OF THE RHEUMATIC DISEASES 0003-4967 ANNALS OF THE RHEUMATIC DISEASES 0003-4967 J. Choe, N. Prodanović, j. Niebrizidovski, i. Staykov, E. Dokoupilova, A. Baranauskaite, R. Yatsyshyn, M. Mekić, W. Porawska, H. Ciferska, K. Jedrichovicz-Rosiak, A. Zielinska, J. Choe, Y. Rho, J. Smolen, SAT0152 A Randomised,Doble-Blind ,Phase III Study Comparing SB2,An Infliximab Biosimilar, To the Infliximab Reference Product (Remicade) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, Jun, 2015 https://pub.unibl.org/s/cir/item/41414